Psychodermatology: a molecular link between psoriasis and anxiety disorder

Eugene Klimov¹²³✉, Artemii Tretiakov¹, Olga Rudko¹, Anna Soboleva⁴, Ivan Danilin⁵, Irina Korsunskaya⁶, Vladimir Sobolev⁷⁸

Abstract

This article describes premises for the development of psychodermatology. An analysis of research literature and data is presented based on the example of psoriasis and anxiety disorder. Protein molecules with altered concentrations in patients with psoriasis and anxiety disorder compared to controls are identified (chemokine [C-C motif] ligand 2, corticotropin-release hormone, growth hormone 1, leptin, and tumor necrosis factor with increased concentration and brain-derived neurotrophic factor with decreased concentration). All molecules are secretory peptides. In the future, the information obtained may make it possible to pursue an in-depth study of the molecular mechanisms underlying psychodermatology.

Keywords: psychodermatology, psoriasis, anxiety disorder, signaling pathways, peptides

Received: 30 March 2018 | Returned for modification: 25 May 2018 | Accepted: 26 June 2018

Introduction

Psychodermatology is an interdisciplinary field combining psychiatry and dermatology. Psychodermatology studies links between skin and mental diseases that occasionally develop in the same patient (1).

Although psychodermatology has only recently gained recognition among researchers, the connection between dermatological and mental disorders first appeared in the literature in the nineteenth century (2). In his 1850 book Diseases of the Skin, Erasmus Wilson characterized several diseases, including alopecia areata (spot baldness), skin hypopigmentation, itching (pruritus), and delusional parasitosis, as “cutaneous neuroses.” This book is considered the beginning of modern psychodermatology (2).

In the early twentieth century, psychodermatological problems rarely appeared in the literature. In 1925, Joseph Klauder highlighted the importance of psychotherapy in the treatment of skin diseases (2). The authors of 1930 article “The effect on the skin of emotional and nervous states” summarized the information on the subject and raised several psychodermatological problems as well (3). However, until the mid-twentieth century, there were no notable studies in psychodermatology (2).

Starting in the 1960s and mostly in recent decades, interest in psychodermatology increased significantly. In spite of the fact that several psychodermatology textbooks are available (4), recent polls have shown that researchers and medical doctors do not have sufficient knowledge of this field. Whereas 42% of dermatologists and 22% of psychiatrists consider themselves capable of diagnosing psychodermatological diseases (1), only 18% of dermatologists and 21% of psychiatrists acknowledged understanding what psychodermatology is (1, 5).

General tendencies

Even in the absence of any pathological processes, psychological states may affect skin condition. Blushing due to emotional stress, sweating when anxious, and paleness as a manifestation of fear are good illustrations of this tendency (6). Apart from these short-term changes, skin condition reflects health condition in general and plays a role in both physical and mental health maintenance (6).

More than a third of patients that suffer from dermatological diseases also have psychological disorders that aggravate their condition (1, 7). In many cases, such patients require not only drug treatment, but also psychological or even psychiatric help (4).

The urgency of this problem is determined by a significant number of skin diseases that act in comorbidity with mental disorders. According to Tress et al., mental disorders appear in 35.5% of dermatological patients (8). The same results were obtained by Picardi et al., who worked on this problem for many years and concluded that in 30 to 40% of cases dermatological diseases are accompanied by mental pathologies (9).

Skin diseases may provoke mental problems associated with shame, anxiety, or depression (2). For the majority of people, their visual appearance, as well as the appearances of other people, play an important role. Even minor changes in skin condition (e.g., mild acne) can cause significant stress in many people, whereas others cope better with a diagnosis of severe skin disease (10). Psoriasis, vitiligo, acne vulgaris, chronic eczema, acne rosacea, neurofibromatosis, Darier’s disease, and some other diseases that affect the appearance of the skin may also affect the psyche by changing a person’s self-image as well as some aspects of his or her social life (10, 11). In these situations, psychological diseases may develop secondary to skin diseases. Helping people to understand the real nature of skin diseases and spreading information about them within the society to prevent stigmatization may significantly lower the damage caused by such diseases (10).

The converse situation is possible because skin is often an object of self-harm and destructive behavior for people suffering from psychological problems, which leads to dermatological...
Psoriasis (psoriasis vulgaris, L40.0) is a chronic inflammatory autoimmune skin disease with a complicated etiology that develops due to both internal (genetic) and external factors. Some researchers suggest that psoriasis is a systemic disease, affecting not only the skin but also various systems and organs (17).

Anxiety disorder (F41.1) is a psychiatric disorder characterized by a sustainable anxiety not caused by any particular objects or situations. Irrational fear of a disease or an accident may be present, as well as some other fears and misgivings (18, 19). There are tendencies toward fluctuation and chronification of the disease (20).

In order to reveal possible common molecular pathways in psoriasis and anxiety disorders, we conducted a search of protein molecules that undergo a quantity change during both diseases. We used the PathwayStudio 9.0 software with the ResNet13 database (Elsevier), which contains information from literature available on the internet. To find the proteins with a changed concentration, we used the “common targets” filter and searched only for links of the QuantitativeChange type. For further study, we only chose proteins with altered concentrations in both psoriasis and anxiety disorder. We identified seven proteins with altered concentrations; the results are shown on Figure 1. Next, we analyzed referenced articles in detail. Articles with statistically significant results and reviews with reference to original papers were taken into consideration. This stage eliminated ADIPOQ (adiponectin, C1Q and collagen) protein because its concentration is altered in patients with migraine and not in patients with anxiety disorder. The results of the analysis of the articles are provided in Table 1.

As shown in Table 1, all the proteins identified are secretory molecules that participate in various intercellular processes, including metabolism regulation, neuron homeostasis, and immune responses. The same patterns of quantitative changes are described for most of these proteins: they are increased in psoriasis and anxiety disorders compared to normal states, with the exception of brain-derived neurotrophic factor (BDNF), the concentration of which is decreased in psoriasis and anxiety disorders.

Data mining showed that these peptides can be divided into further groups according to the type of processes they take part in: 1) catabolism: growth hormone 1 (GH1) and leptin (LEP); 2) neuron homeostasis: BDNF; 3) immune response: chemokine (C-C motif) ligand 2 (CCL2) and tumor necrosis factor (TNF); and 4) behavioral reactions: corticotropin-release hormone (CRH).

Among all the peptides found in this study, the most promising is CRH, which is a stress hormone that releases in case of anxiety, fear, or stress. Prolonged exposure to CRH induces depression, anxiety, and insomnia (52). An increased concentration of this peptide in psoriasis and anxiety disorders may be an evidence of similarities in their pathogenesis. The pro-inflammatory role of CRH is noted in many studies, some of which demonstrate increased expression of CRH and CRH-receptor in the affected skin of patients with psoriasis (53). Other molecules may play a role in pathogenesis as well, activating similar pathways in different tissues.

A distinctive feature of the regulatory peptides is pleiotropy, or the ability to affect several different physiological functions. On the other hand, many physiological functions undergo similar changes under the influence of various regulatory peptides. In addition, peptides are capable of mutual regulation of expression. For example, the expression of CRH may be activated by TNF (54), BDNF (55), and LEP (56). CRH, meanwhile, regulates TNF expression (57), BDNF expression (58), and GHI release (59). According to the ResNet13, similar relations exist between other proteins stud-
ied; for example, GH1 regulates LEP, CCL2, and TNF expression; CCL2 regulates TNF expression; TNF regulates CCL2, BDNF, LEP, and GH1 expression; and LEP regulates BDNF, CRH, GH1, and CCL2 expression. Further studies may elucidate the link between the pathogenesis of psoriasis and anxiety disorder.

**Conclusion**

This review discusses the relationship between the skin and psyche, and it identifies possible correlations between the molecular comorbidity of psoriasis and anxiety disorders. The six molecules (BDNF, CCL2, GH1, CRH, LEP, and TNF) considered as common points for both conditions are signaling peptides that can modulate a variety of cellular and physiological processes. This review may elucidate possible factors and processes involved in the pathogenesis of both psoriasis and anxiety disorder, inspiring other researchers to undertake more detailed research on the most important psychodermatological mechanisms.

---

**Table 1** Proteins and their links to psoriasis and anxiety disorder in alphabetical order. Functions are listed according to NCBI (https://www.ncbi.nlm.nih.gov/gene).

<table>
<thead>
<tr>
<th>Gene, description</th>
<th>Link to psoriasis</th>
<th>Link to anxiety disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDNF (brain-derived neurotrophic factor) responsible for growth and homeostasis of brain neurons</td>
<td>Lowered in patients with psoriasis, depression (21), chronic stress (22)</td>
<td>Lowered in patients with anxiety disorders (23–26)</td>
</tr>
<tr>
<td>CCL2 (chemokine (C-C motif) ligand 2) activates chemotaxis in monocytes and basophils</td>
<td>Significant increase in serum of patients with psoriasis (27, 28)</td>
<td>Increased in patients with anxiety disorder (29)</td>
</tr>
<tr>
<td>GH1 (growth hormone) required for control of body height</td>
<td>Increased in patients with skin diseases, including psoriasis (30)</td>
<td>Increased in patients with stress and anxiety disorder (31)</td>
</tr>
<tr>
<td>CRH (corticotropin-releasing hormone) is synthesized in response to stress and stimulates release of adrenocorticotropic</td>
<td>Significant increase in serum of patients with psoriasis (32)</td>
<td>Increased in patients with anxiety disorder (31, 33, 34)</td>
</tr>
<tr>
<td>LEP (leptin) is secreted by adipocytes, regulates fat and energy metabolism, as well as some endocrine functions and an inflammatory/immune response</td>
<td>Increased in patients with psoriasis (35–42)</td>
<td>Increased in patients with anxiety disorder (43)</td>
</tr>
<tr>
<td>TNF (tumor necrosis factor), a multifunctional proinflammatory cytokine, is involved in the regulation of a variety of cellular and physiological processes</td>
<td>Significant increase of expression in serum and skin of patients with psoriasis (44–50)</td>
<td>Increased in patients with anxiety disorder and systemic lupus erythematosus (51)</td>
</tr>
</tbody>
</table>

---

**Figure 1** Proteins with altered expression linked with both psoriasis and anxiety disorders.

